I wouldn't scoff at that, it isn't strange at all. £500m for similar compounds is probably in the mid range of dealsl, they could be worth more but to get more, I believe we'd have to take it into phase II ourselves.
I still believe this all adds up to the fact that his hands are tied because of ongoing discussions.. They know we are going to find this stuff anyway and this way the herd doesn't come along to mess everything up.
If it's not newsworthy he should not have flagged it in may as not newsworthy.
He flagged the newsflow. We know tyk 2 has filed it's reports with innovate UK. We know subsequent studies have started with 3rd parties. So what the complete contempt for shareholders. Promising news. And then giving it to other sources but not your shareholders. Why flag the potential newsflow in may and thenot withhold. It's not unrealistic expectations. It is expectations that the bod set themselves publicly that they have failed to deliver on. Where is the tyk2 innovate UK funded research that delivered in August?
The line is.. 85% of takeovers in the US are subject to lawsuits for conflict of interest of directors. Mostly the directors are keener to ensure continuing employment and do a deal in detriment to other shareholders. The website has been cleaned up this week. We had the Berlin listing last week. Being wise in foresight better than in hindsight. My money is in AZN for chk1 (poss with lilly). And j&J for the rest of the company including skil.
I know a lot may scoff at a 4/500m buyout but stranger things have happened, albeit there is little incentive to go in with a high offer other than the hopeful avoidance of a bidding war?
For those thinking who can afford it etc, granted a totally different field but I would use the case of BP for how monster corporations fund things. Their Macondo oil well disaster resulted in an $18.7 billion fine spread over 18 years. That's $3 million a day and yet the dividend wasn't touched. That's the sort of buying power for corporations of that size. Chicken feed to your GSKs or your AZNs. Chicken feed.
I have an alternative view that takeover discussions have been underway since Parker was appointed. So planned news hasn't been released. It may not materialise as it didn't in 2011. But we will know soon enough. Gla
Firstly, it was the failure of the BOD to appropriately and timeously release an appropriately worded rns informing both 'The Market', along with the company's shareholders of the below compound back in 2013 which, when the info was eventually recently 'teased out of the BOD' confirmed the beneficial effect of the compound CCT244747 in respect of the treatment of BOTH head and neck cancers, when combined with radiotherapy:
In conclusion, the above info only serves to confirm my own personal suspicions that, 'Timbo' has and indeed, continues to play 'fast and loose' with the company's corporate news-flow and by default, the company's corresponding sp/market cap. In so doing, said actions have, I firmly believe, served to keep SAR under the radar and associated scrutiny of Institutional Investors and in so doing has enabled the BOD of SAR, for far too long, to run this organisation as their "personal fiefdom."
However, whilst the above ruminations along with several other concerns which I harbor in respect of the running of SAR by the current management may, or may not, prove to be correct, I have every faith in the ability of the FCA in determining that fact and to that end, I await the outcome of their evaluation in due course!
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.